KLK2-comPAS — Pasritamig versus placebo in late-line metastatic castration-resistant prostate cancer (KLK2-comPAS)

Phase 3 · Prostate Cancer

Population

Late-line metastatic castration-resistant prostate cancer that has progressed on prior standard therapies.

Primary Endpoint

Overall survival

Rationale

Metastatic castration-resistant prostate cancer eventually exhausts hormonal, chemotherapy, and radioligand options. KLK2-comPAS tests whether a first-in-class KLK2-directed T-cell engager can extend survival in heavily pretreated disease, validating KLK2 as a prostate-restricted immunotherapy target.

What It Could Change

Could establish a KLK2-directed bispecific T-cell engager as a new immunotherapy option for late-line castration-resistant prostate cancer.